{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:57:35Z","timestamp":1791158255703,"version":"4.1.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Management of type 2 diabetes mellitus (T2DM) during Ramadan fasting presents unique challenges due to prolonged fasting periods, irregular meal schedules, and altered medication timing, potentially impacting glycemic control. Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been shown to improve glycemic control in T2DM effectively. However, the effectiveness of ertugliflozin during Ramadan fasting, a period with unique glycemic challenges, has not been studied extensively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was a multicenter, real-life experience study involving 1373 adult patients with known T2DM for at least one year, an HbA1c level of less than 10%, and who intended to fast during Ramadan. Participants were divided into two groups: the Ertu group (n=703), consisting of patients who had been on a stable dose of ertugliflozin for at least three months before Ramadan, and the non-Ertu group (n=670), which included patients receiving other oral antihyperglycemic drugs (OADs) except ertugliflozin. Patients attended a baseline visit one month before the first day of Ramadan and a follow-up visit within one month after the last day of Ramadan. Both visits included history taking, physical examinations, and laboratory tests. The primary endpoints were changes in HbA1c levels, body weight, body mass index (BMI), and the incidence of hypoglycemia during Ramadan fasting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age of the study participants was 50.37 \u00b1 11.14 (SD) years, with 40.6% male and 58.7% female. Patients receiving ertugliflozin showed significant reduction in HbA1C (-0.65 \u00b1 0.67% vs. -0.22 \u00b1 0.64%, p&amp;lt;0.001), body weight (-1.24 \u00b1 2.58 kg vs. -0.36 \u00b1 3.41 kg, p&amp;lt;0.001), and BMI (-0.48 \u00b1 1.03 kg\/m\u00b2 vs. -0.11 \u00b1 1.33 kg\/m\u00b2, p&amp;lt;0.001) compared to the non-Ertu group. Hypoglycemia was reported in 0.3% of the ertugliflozin group and 0.7% of the other group, with comparable adverse events (p=.23; \u22650.05), indicating a favorable safety profile for ertugliflozin during fasting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates that ertugliflozin is effective and safe for patients with T2DM during Ramadan fasting.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1542946","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:11:32Z","timestamp":1739250692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study)"],"prefix":"10.3389","volume":"16","author":[{"given":"Md Faruque","family":"Pathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazma","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marufa","family":"Mustari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saifuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza","family":"Sharifuzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Motiur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ripon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Mohiuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B. M.","family":"Kamrul-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Abdul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shah","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Mahjabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faria","family":"Afsana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Abu","family":"Bakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahniyah","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsar","family":"Ahammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Kumar","family":"Talukder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahjada","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03563.x","article-title":"Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education","volume":"29","author":"Ahmedani","year":"2012","journal-title":"Diabetes Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1220-8","article-title":"Ramadan-focused education and awareness in type 2 diabetes","volume":"52","author":"Hassanein","year":"2009","journal-title":"Diabetologia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/hex.2015.18.issue-5","article-title":"Having diabetes and having to fast: a qualitative study of british Muslims with Diabetes","volume":"18","author":"Patel","year":"2015","journal-title":"Heal Expect"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.diabres.2017.07.014","article-title":"CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents","volume":"132","author":"Jabbar","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.10.2306","article-title":"A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422\/2001 (EPIDIAR) study","volume":"27","author":"Salti","year":"2004","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"108122","DOI":"10.1016\/j.diabres.2020.108122","article-title":"The effect of Ramadan focused education on patients with type 2 diabetes: A systematic review and meta-analysis","volume":"162","author":"Gad","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"109185","DOI":"10.1016\/j.diabres.2021.109185","article-title":"Diabetes and ramadan: Practical guidelines 2021","volume":"185","author":"Hassanein","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-022-01168-3","article-title":"Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study","volume":"22","author":"Ahmed","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S54683","article-title":"Fasting during Ramadan: Efficacy, safety, and patient acceptability of vildagliptin in diabetic patients","volume":"8","author":"Aziz","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12249","article-title":"metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial original article","author":"Brady","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2018.21","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) during the month of ramadan in muslim patients with type 2 diabetes","volume":"33","author":"Bashier","year":"2018","journal-title":"Oman Med J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2015.09.001","article-title":"Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis","volume":"10","author":"Loh","year":"2016","journal-title":"Prim Care Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2015.17.issue-7","article-title":"Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis","volume":"17","author":"Gray","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.578245","article-title":"Ramadan Study Group Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study","volume":"27","author":"Aravind","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjdrc-2020-001248","article-title":"Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA\/EASD consensus","volume":"8","author":"Ibrahim","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12249","article-title":"A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial","volume":"16","author":"Brady","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2016.18.issue-10","article-title":"Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial","volume":"18","author":"Azar","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.4172\/2155-6156.1000590","article-title":"Safety and efficacy of liraglutide as an add-on therapy to pre-existing anti-diabetic regimens during Ramadan, a prospective observational trial","volume":"6","author":"Khalifa","year":"2015","journal-title":"J Diabetes Metab Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02391.x","article-title":"Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial","volume":"25","author":"Pan","year":"2008","journal-title":"Diabetes Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/dc24-SREV","article-title":"Summary of revisions: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: A clinical guideline from the American college of physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00592-016-0856-y","article-title":"Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Solini","year":"2016","journal-title":"Acta Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw110","article-title":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","volume":"37","author":"Marx","year":"2016","journal-title":"Eur Hear J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0878-6","article-title":"Ertugliflozin: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2017.19.issue-5","article-title":"efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2018.20.issue-6","article-title":"Longterm efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study","volume":"20","author":"Aronson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0358-0","article-title":"Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study","volume":"9","author":"Miller","year":"2018","journal-title":"Diabetes Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2018.20.issue-3","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(23)00032-6","article-title":"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial","volume":"4","author":"Pratley","year":"2023","journal-title":"Lancet Heal Longev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-021-00806-2","article-title":"Ramadan fasting and diabetes, latest evidence and technological advancements: 2021 update","volume":"20","author":"Tootee","year":"2021","journal-title":"J Diabetes Metab Disord"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jcjd.2018.04.007","article-title":"Diabetes Canada position statement for people with types 1 and 2 diabetes who fast during Ramadan","volume":"43","author":"Bajaj","year":"2019","journal-title":"Can J Diabetes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12020-022-03290-7","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population\u2014an observational study from a tertiary care center in Karachi","volume":"80","author":"Sheikh","year":"2023","journal-title":"Endocrine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S380544","article-title":"Efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: A real-world study from Bangladesh","volume":"15","author":"Pathan","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2016.18.issue-6","article-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia","volume":"18","author":"Wan Seman","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.04.022","article-title":"Safety and tolerability of empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: a prospective cohort study","volume":"31","author":"Samkari","year":"2023","journal-title":"Saudi Pharm J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.diabres.2018.05.022","article-title":"The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes","volume":"142","author":"Shao","year":"2018","journal-title":"Diabetes Res Clin Pr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijcp.2017.71.issue-10","article-title":"Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)","volume":"71","author":"Hassanein","year":"2017","journal-title":"Int J Clin Pract."},{"key":"B39","volume-title":"Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment","year":"2000"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5527\/wjn.v8.i1.23","article-title":"Dehydration and volume depletion: How to handle the misconceptions","volume":"8","author":"Asim","year":"2019","journal-title":"World J Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ofid\/ofad332","article-title":"Definitions of urinary tract infection in current research: A systematic review","volume":"1","author":"Bilsen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"B43","unstructured":"National guidelines for management of hypertension in Bangladesh\n          \n          2013"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-94947-2","article-title":"Prevalence of and factors associated with hypertension according to JNC 7 and ACC\/AHA 2017 guidelines in Bangladesh","volume":"11","author":"Rahman","year":"2021","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0280672","article-title":"Prevalence and factors associated with dyslipidemia in Bangladeshi adults","volume":"18","author":"Ali","year":"2023","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02597-6","article-title":"Prevalence of chronic kidney disease in Bangladesh: a systematic review and meta-analysis","volume":"53","author":"Banik","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1210\/jendso\/bvad011","article-title":"Prevalence of admission hyponatremia in patients with diabetes treated with and without an SGLT2 inhibitor","volume":"9","author":"Monnerat","year":"2023","journal-title":"J Endocr Soc"},{"key":"B48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/medicina58030431","article-title":"Hypokalemia in diabetes mellitus setting","volume":"58","author":"Coregliano-Ring","year":"2022","journal-title":"Medicina (B Aires)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0097","article-title":"Overview of ertugliflozin","volume":"37","author":"Nguyen","year":"2019","journal-title":"Clin Diabetes"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033198","article-title":"Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"102","author":"Cheng","year":"2023","journal-title":"Med (United States)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2021-055044","article-title":"Diabetes among adults in Bangladesh: changes in prevalence and risk factors between two cross-sectional surveys","volume":"12","author":"Chowdhury","year":"2022","journal-title":"BMJ Open"},{"key":"B53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12902-022-00938-3","article-title":"Prevalence and predictors of diabetes distress among adults with type 2 diabetes mellitus: a facility-based cross-sectional study of Bangladesh","volume":"22","author":"Kamrul-Hasan","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B54","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12902-022-01072-w","article-title":"Assessment of quality of life and its determinants in type-2 diabetes patients using the WHOQOL-BREF instrument in Bangladesh","volume":"22","author":"Amin","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-019-4440-3","article-title":"Type 2 diabetes mellitus in Bangladesh: A prevalence based cost-of-illness study","volume":"19","author":"Afroz","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036086","article-title":"Prevalence of diabetes and pre-diabetes in Bangladesh: a systematic review and meta-analysis","volume":"10","author":"Akhtar","year":"2020","journal-title":"BMJ Open"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076261","article-title":"Prevalence of comorbidities and its associated factors among type-2 diabetes patients: a hospital-based study in Jashore District, Bangladesh","volume":"13","author":"Shuvo","year":"2023","journal-title":"BMJ Open"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.21037\/jxym-20-96","article-title":"Overweight and obesity among the urban and rural type 2 diabetic subjects in Bangladesh","volume":"5","author":"Banik","year":"2020","journal-title":"J Xiangya Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13098-023-01120-y","article-title":"Comparison of fasting and random lipid profiles among subjects with type 2 diabetes mellitus: an outpatient-based cross-sectional study in Bangladesh","volume":"15","author":"Kamrul-Hasan","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-023-01522-z","article-title":"Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study","volume":"23","author":"Selim","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"B61","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.jcte.2023.100315","article-title":"Risk stratification using the 2021 IDF-DAR risk calculator and fasting experience of Bangladeshi subjects with type 2 diabetes in Ramadan: The DAR-BAN study","volume":"31","author":"Kamrul-Hasan","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/aam.aam_63_17","article-title":"Effect of ramadan fasting on glycemic control and other essential variables in diabetic patients","volume":"17","author":"Bener","year":"2018","journal-title":"Ann Afr Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1347247","article-title":"The impact of fasting during Ramadan on the glycemic control of patients with type 2 diabetes mellitus","volume":"121","author":"Sahin","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B64","article-title":"Glycemic control among pregnant diabetic women on insulin who fasted during Ramadan","volume":"36","author":"Ismail","year":"2011","journal-title":"Iran J Med Sci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ijcp.12991","article-title":"Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)","volume":"142","author":"Hassanein","year":"2018","journal-title":"Int J Clin Pract"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1542946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:11:39Z","timestamp":1739250699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1542946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":65,"alternative-id":["10.3389\/fendo.2025.1542946"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1542946","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"article-number":"1542946"}}